For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
IGF-1 LR3 is an 83-amino-acid synthetic analogue of human IGF-1, engineered with two structural modifications that reduce binding to IGF-binding proteins (IGFBPs) by approximately 1,000-fold and extend half-life from the native IGF-1's 10 to 15 minutes to approximately 20 to 30 hours. It is primarily used as a cell culture additive for maintaining human pluripotent stem cells, organoids, and biopharmaceutical production. Zero human clinical trials have been completed. All anabolic, body composition, and recovery claims originate from animal studies and mechanistic extrapolation from native IGF-1 data. The cancer risk signal from IGF-1 receptor biology is the most significant safety concern and is unsettled. This is the highest-risk compound in this research series from an evidence-to-use-pattern mismatch perspective.
The complete IGF-1 LR3 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use